ResMed Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ResMed Inc. on April 30, 2026, reporting events occurring on April 24, 2026. The filing addresses significant changes in executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a successor.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and personnel changes.
Material Changes
- Departure of CFO: Brett Sandercock will retire as Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer effective May 4, 2026.
- Transition Role: Mr. Sandercock will serve as Special Advisor to the CEO through December 31, 2026, and in a consulting role from January 1, 2027, through December 31, 2027.
- Appointment of New CFO: Aaron Bloomer, age 40, was appointed as Chief Financial Officer, effective May 4, 2026. He previously served as CFO at Exact Sciences Corporation.
Compensation and Outlook
Outgoing Executive Compensation: Mr. Sandercock will retain his current salary and benefits, continue vesting of long-term equity incentives, and remain eligible for a pro-rata short-term incentive payment for fiscal year 2027.
Incoming Executive Compensation: Mr. Bloomer's compensation package includes:
- Annual base salary of $725,000.
- Sign-on bonus of $150,000 (subject to repayment if he voluntarily terminates within 24 months).
- Annual short-term cash incentive target of 80% of base salary (pro-rated for fiscal year 2026).
- Sign-on long-term performance equity grant valued at $3,300,000, split equally between executive restricted stock units and performance stock units (based on absolute and relative total shareholder return).
- Eligibility for an additional equity grant of $3,300,000 in November 2026 for fiscal year 2027, subject to Board approval.
- Relocation assistance to San Diego.
Risks and Contingencies: The filing states that Mr. Sandercock's retirement did not result from any disagreement with the Company regarding operations, policies, or practices. There are no related party transactions requiring disclosure.
Investor Verification Checklist
- Verify the effective date of the CFO transition (May 4, 2026) and the interim advisory period.
- Review the signed offer letter for Aaron Bloomer, which will be filed as an exhibit to the Form 10-Q for the quarter ended March 31, 2026.
- Confirm the specific vesting schedules and performance metrics for the $3,300,000 equity grants.
- Monitor future filings for the Board's approval of the fiscal year 2027 equity grant for Mr. Bloomer.